CANTARGIA AB
556791-6019ActiveDeveloping antibody-based drugs targeting IL1RAP for serious diseases.
Overview
- 20–49
- Employees
- ≤1K SEK
- Revenue
- 2009
- Founded
Key Decision Makers
Hilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
+6 more contacts in Funnelfeedr
Description
Cantargia is a biotechnology company focused on developing innovative antibody-based therapeutics. Their primary scientific target is the protein IL1RAP, which plays a role in several serious conditions. The company's mission is to create treatments for cancer as well as autoimmune and inflammatory...
Tags
Keywords
Tech Stack
Company Information
- Industry
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Legal Form
- Aktiebolag
- VAT Number
- SE556791601901
Decision Makers
10 contacts in FunnelfeedrHilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
Patrik Renblad
Chief Financial Officer
Flavia Borellini
Board Member
Ton Berkien
Chief Business Officer
David Liberg
Chief Scientific Officer
Jenny Sundqvist
Board Member
Anders Martin-Löf
Board Member
Similar Companies
20 similar companies in FunnelfeedrHamlet BioPharma AB
5–9 employeesInnovative pharmaceutical company developing targeted cancer and infection treatments.
Alligator Bioscience AB
10–19 employeesClinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Beactica Therapeutics AB
6 employeesPrecision medicine company developing novel therapeutics via targeted protein degradation.
BioGaia Pharma AB
0 employeesDeveloping and out-licensing novel biotherapeutic platforms from microbiome research.
Nanohumps Biosciences Oy
Pioneering revolutionary cancer therapies using proprietary nanosized antibodies.
Browse More
CANTARGIA AB Questions
Want to see Funnelfeedr in action?
Book a free demo and discover how Funnelfeedr helps you find and convert your ideal customers.
Book a demo